Jpmorgan Chase & CO Chembio Diagnostics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.25 - $0.45 $506 - $912	-2,027 Reduced 57.59%	1,493 $0
Q4 2022 Feb 13, 2023	BUY	$0.2 - $0.33 $25 - $41	126 Added 3.71%	3,520 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $1.1 $175 - $550	-500 Reduced 12.84%	3,394 $1,000
Q2 2022 Aug 11, 2022	SELL	$0.45 - $0.8 $269 - $479	-599 Reduced 13.33%	3,894 $3,000
Q1 2022 May 11, 2022	SELL	$0.66 - $1.23 $19,112 - $35,619	-28,959 Reduced 86.57%	4,493 $4,000
Q4 2021 Feb 10, 2022	BUY	$1.09 - $2.55 $34,920 - $81,694	32,037 Added 2264.1%	33,452 $38,000
Q3 2021 Nov 12, 2021	BUY	$2.06 - $5.34 $2,914 - $7,556	1,415 New	1,415 $4,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.